neurovax
Biologicalexperimental
Neurovax is a vaccine designed to treat patients with multiple sclerosis. Developed by Immune Response BioPharma, Inc. it is currently in phase II clinical trials. Neurovax is designed to stimulate FOXP3+ regulatory T-cells that can then suppress the autoreactive T-cells in some patients. — Wikipedia
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2017 (NCT02057159)
Timeline
Indications
Studied for
Mechanism of action
- regulatory t cellsSupplementation
regulatory t cells supplementation
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02200718 | Phase 1 | Nov 1, 2017 | Oregon Health and Science University, The Immune Response Corporation |
| NCT02149706 | Phase 2 | Mar 1, 2017 | Oregon Health and Science University, The Immune Response Corporation |
| NCT02057159 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2017 | Oregon Health and Science University, The Immune Response Corporation |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Oregon Health and Science University | Academic/Hospital | 3 | 0 | 3 | 2017 |
| The Immune Response Corporation | For profit | 3 | 3 | 3 | 2017 |
2 organizations
Page 1 / 1